Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | KMO | O15229 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648842 | 0.86 | KCNH2 (0.45) | KCNH2KMOSIGMAR1F2RL3AHR | |
| SCHEMBL5025698 | 0.84 | MAPT (0.47) | KCNH2KMT2ACYP11B1HSD11B1CYP1A2 | |
| SCHEMBL29894745 | 0.78 | DYRK1B (0.42) | CYP11B1HSD11B1 | |
| SCHEMBL4806553 | 0.77 | RPA1 (0.48) | CYP1A2CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL15635313 | 0.77 | CYP11B1 (0.57) | PHGDHKMT2ACYP11B1HSD11B1MAPT | |
| SCHEMBL3223296 | 0.77 | KMT2A (0.49) | KMOSIGMAR1F2RL3AHRKMT2A | |
| SCHEMBL11962167 | 0.76 | MEN1 (0.49) | PHGDHKMT2AMAPT | |
| SCHEMBL4685144 | 0.74 | TLR8 (0.42) | SIGMAR1F2RL3CYP11B1HSD11B1 | |
| SCHEMBL2555009 | 0.74 | KMO (0.50) | KMOPHGDHKMT2A | |
| SCHEMBL13062641 | 0.73 | MAPT (0.43) | KCNH2KMOSIGMAR1F2RL3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | KCNH2 2025/4885KMO 1879/4885SIGMAR1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.